Stay updated on Pembrolizumab Combo in PD-1 Refractory Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in PD-1 Refractory Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab Combo in PD-1 Refractory Melanoma Clinical Trial page
- Check2 days agoChange DetectedFooter version badge updated from v3.6.0 to v3.6.2, indicating an upgrade to the site's interface/version. This change does not alter study data, eligibility, or results on the page.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedRecruitment status updated to no longer look for participants, indicating enrollment has closed. The page history now lists revision v3.6.0 and removes the prior revision v3.5.5.SummaryDifference0.2%

- Check24 days agoChange DetectedThe site footer now shows Revision: v3.5.5, replacing the previous v3.5.4, signaling a new platform release. This update does not modify study records or visible page content.SummaryDifference0.0%

- Check46 days agoChange DetectedA new revision v3.5.4 was added to the study record history, superseding the previous v3.5.3. This update records the latest page changes.SummaryDifference0.0%

- Check60 days agoChange DetectedThe page's revision history now lists Revision: v3.5.3. The previous entry Revision: v3.5.2 is removed from the history listing.SummaryDifference0.0%

- Check75 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2 in the page metadata (footer), a technical version change with no impact on study content.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab Combo in PD-1 Refractory Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in PD-1 Refractory Melanoma Clinical Trial page.